Jonathan Harris is a partner in the Corporate and Litigation Departments and a member of the Life Sciences Practice Group. A patent lawyer and business-minded MBA with over two decades of experience, Jonathan helps clients protect, license and exploit their most critical innovations. He advises established and emergent life science companies on all aspects of IP matters, including patent licenses and strategic alliances, litigation, IP diligence, freedom to operate, and prosecution.
Clients describe Jonathan as “an excellent patent analyst” and “skilled at translating complex technical subjects into English.” He works with start-ups to develop and license key IP assets. He has also worked extensively with global industry leaders on products worth billions of dollars. Given his MBA, Jonathan tries to see the bigger picture of every matter — not only from a legal, but also a commercial perspective. His many years of high stakes patent litigation experience help clients see around corners and reduce litigation risk. He serves as outside general counsel to clients and their boards of directors.
Jonathan has also prepared and prosecuted over two hundred patents and served as lead or co-lead trial counsel in numerous Paragraph IV actions over pharmaceutical products, including Cialis® (tadalafil), Diclegis® (doxylamine succinate, pyridoxine HCl), Focalin® (dexmethylphenidate HCl), Ritalin® (methylphenidate HCL), Trilipix® (fenofibric acid), and Zometa® (Zoledronic Acid), among others. He is intimately familiar with the overlying FDA regulatory regime in the pharmaceutical area.
- University of Connecticut School of Law (J.D.)
- cum laude
- University of Connecticut School of Business (M.B.A.)
- cum laude
- Duke University (B.S.)
I have been providing client advice as both a USPTO-registered Patent Agent and Attorney for over 15 years. My private practice focused on drafting PTC and US patent applications, prosecuted US patent applications, and provided opinion and due diligence support to the attorneys at the firm for academic, US, and multinational corporations in relation to pharmaceutical, biologics, diagnostics, and gene therapies. My in-house roles have focused on providing clearance, due diligence, and litigation activities related to branded and generic pharmaceutical products that are manufactured at sites throughout the globe and are marketed in the Americas.